Reuters logo
BRIEF-Ablynx: Results support advancement of vobarilizumab into phase III development
February 9, 2017 / 6:38 AM / in 8 months

BRIEF-Ablynx: Results support advancement of vobarilizumab into phase III development

Feb 9 (Reuters) - Ablynx NV:

* Ablynx to present additional data for its anti-IL-6R nanobody, vobarilizumab, a potential best-in-class treatment for rheumatoid arthritis

* Data show that in patients with active RA despite use of methotrexate, treatment with vobarilizumab (150mg q4w, 150mg q2w and 225mg q2w) had a positive impact on disease activity with a compelling safety profile

* Overall, results support advancement of vobarilizumab into phase III development Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below